Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy

Authors


Dr. Rana Karabudak, Hacettepe University School of Medicine, Department of Neurology Neuroimmunology Unit, Sihhiye, 06100, Ankara, Turkey
Tel.: 00 90 312 3051983
Fax: 00 90 312 3051983
e-mail: rkbudak@hacettepe.edu.tr

Abstract

Kurne A, Guc D, Canpinar H, Aydin ÖF, Sayat G, Yörübulut M, Esendagli G, Karabudak R. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy.
Acta Neurol Scand: 2011: 123: 8–12.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard.

Objectives –  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and B cell-activating factor (BAFF), the members of tumor necrosis factor superfamily, play essential roles in immune homeostasis and may have potential contributions to the autoimmune process in multiple sclerosis (MS).

Material and methods –  Thirty-five relapsing remitting MS (RRMS) patients and 19 healthy individuals were enrolled in the study. The expression of TRAIL on peripheral blood lymphocytes was analyzed by flow cytometry. The serum levels of soluble TRAIL (sTRAIL) and soluble BAFF (sBAFF) were determined by ELISA. Further, we evaluated the effect of IFN-β on sTRAIL, sBAFF levels and on TRAIL surface expression in these patients on the third and sixth months following the treatment.

Results and conclusion –  These preliminary results signify that MS patients are heterogenous in TRAIL expression. Additionally, during the IFN-β treatment, the soluble form of TRAIL increases concomitantly as its surface expression decreases on lymphocytes. The basal sBAFF levels of patients were significantly higher than the control group and no significant change was observed. Thus, the changes in TRAIL expression may be a potential parameter indicating the response to IFN-β1 therapy at individual level.

Ancillary